NeuroPace reports preliminary Q4 2021 revenue of $11.0M (+2% YoY); FY2021 $45.2M (+10% YoY)

NeuroPace Inc

Q4 2021 revenue ~$11.0M (+2% YoY); initial implant $8.5M (+10%), replacement $2.5M (-19%).
FY2021 revenue ~$45.2M (+10% YoY); initial implant $33.7M (+20%), replacement $11.5M (-12%).
150 centers performed RNS implant in 2021, up 14% from 132 centers in 2020.
Enrolled first patient in adolescent study to expand indications beyond current pool.
Full Q4 and FY results expected in mid-March 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.